Details for Patent: 5,599,821

Title:	4-heteroaryl-1-piperidinealkylamines and derivatives thereof and their therapeutic utility
Abstract:	Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Inventor(s):	Glamkowski; Edward J. (Warren, NJ), Chiang; Yulin (Covent Station, NJ), Strupczewski; Joseph T. (Flemington, NJ), Bordeau; Kenneth J. (Kintnersville, PA), Nemoto; Peter A. (Raritan, NJ), Tegeler; John J. (Bridgewater, NJ)
Assignee:	Hoechst-Roussel Pharmaceuticals, Inc. (Somerville, NJ)
Filing Date:	Jun 06, 1995
Application Number:	08/469,357
Claims:	1. A compound of the formula: ##STR133## wherein X is --O--, --S--, --NH--, or --N(R.sub.2)--; R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenysulfonyl groups; aryl is as defined hereinafter; p is 1 or2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino; R.sub.1 is --CR.sub.24 R.sub.27 --(CR.sub.23 R.sub.24).sub.n --CR.sub.24 R.sub.27 -- wherein n is 0, 1, 2, or --CHR.sub.24 --CH.dbd.CH--CHR.sub.24 --, --CHR.sub.24 --C.dbd.C--CHR.sub.24 --, --CHR.sub.24 --CH.dbd.CH--CR.sub.23 R.sub.24 --CHR.sub.24 --, --CHR.sub.24 --CR.sub.23 R.sub.24 --CH.dbd.CH--CHR.sub.24 --, --CHR.sub.24 --CH.dbd.C--CR.sub.23 R.sub.24 --CHR.sub.24 --, or --CHR.sub.24 --CR.sub.23 R.sub.24 --C.dbd.C--CHR.sub.24 --, the --CH.dbd.CH--bond being cis or trans; R.sub.23 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy, C.sub.1 -C.sub.18)alkoxy, aryloxy, aryl(C.sub.1 -C.sub.18)alkyloxy, (C.sub.1 -C.sub.18)alkanoyloxy, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, phenyl (C.sub.1 -C.sub.6)alkoxy, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl, or ##STR134## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2, or halogen, and p is as previously defined; and R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6) alkyl, phenyl(C.sub.1 -C.sub.6)alkyloxy, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl, or ##STR135## where Z.sub.1 is as previously defined, and p is as previously defined; R.sub.27 is hydrogen or R.sub.24 and R.sub.27 taken together with the carbon to which they are attached form C.dbd.O or C.dbd.S; and R.sub.18 and R.sub.19 are independently selected from the group consisting of: hydrogen, (C.sub.1 -C.sub.18 straight or branched chain)alkyl, --C(.dbd.O)--O--(C.sub.1 -C.sub.18)alkyl, --C(.dbd.O)--(C.sub.1 -C.sub.18)alkyl, --C(--O--)-pyridyl, ##STR136## where NR.sub.18 R.sub.19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl; where the piperidinyl or piperazinyl ring is optionally substituted by ##STR137## where X, Y, and P are as previously defined; where R.sub.4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C.sub.1 -C.sub.6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C.sub.1 -C.sub.18)acyl amino, (C.sub.1 -C.sub.18)alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, --O--C(.dbd.O)--(C.sub.1 -C.sub.18)straight or branched chain)alkyl or --C(.dbd.O)-aryl; where R.sub.28 is hydrogen, (C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.6)alkyl, phenyl, or substituted phenyl; in which aryl is phenyl or ##STR138## wherein R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18) carboxylic group, in addition, any nitrogen atom may alternatively by acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group; m is 1, 2, or 3; with the proviso that when X is --O-- and Y is hydrogen, lower alkyl, lower alkoxy, chlorine, fluorine, bromine, iodine, or a hydroxyl group, R.sub.18 and R.sub.19 are not lower alkyl; with the proviso that R.sub.18 and R.sub.19 are not hydrogen when R.sub.1 is (CH.sub.2).sub.2-5 --, X is --O--, and Y is 6-F; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof. 2. The compound of claim 1, wherein X is --N(R.sub.2)--. 3. The compound of claim 2, wherein R.sub.2 is (C.sub.1 -C.sub.18)alkanoyl or (C.sub.1 -C.sub.18)alkoxycarbonyl. 4. The compound of claim 1, wherein R.sub.18 and R.sub.19 are hydrogen. 5. The compound of claim 4, which is 2-[4-[(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]amine and its pharmaceutically acceptable acid addition salts. 6. The compound of claim 4, which is 2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propyl]amine. 7. The compound of claim 4, which is 3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-hydroxy-1-propylami ne and its pharmaceutically acceptable acid addition salts. 8. The compound of claim 1, wherein R.sub.18 is hydrogen and R.sub.19 is --(C.dbd.O)pyridyl. 9. The compound of claim 8, which is N-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3-pyridineca rboxamide and its pharmaceutically acceptable acid addition salts. 10. The compound of claim 1, wherein R.sub.18 is hydrogen and R.sub.19 is ##STR139## 11. The compound of claim 1, wherein NR.sub.18 R.sub.19 form a piperidinyl ring. 12. The compound of claim 11, which is 1,2-bis-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethane and its pharmaceutically acceptable acid addition salts. 13. The compound of claim 11, which is 1,2-bis-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2hydroxypropane and its pharmaceutically acceptable acid addition salts. 14. (S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropyl methyl carbamate and its pharmaceutically acceptable acid addition salts. 15. An antipsychotic composition, which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier. 16. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 1. 17. An analgesic composition, which comprises the compound of claim 1 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier. 18. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 1. 19. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1, wherein the compound contains an acylated hydroxy group, or an acylated amino group. 20. The depot pharmaceutical composition of claim 8, wherein the hydroxy group is acylated, or the amino group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group. 21. The composition of claim 19, which contains a pharmaceutically acceptable oil. 22. The composition of claim 21, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 23. The composition of claim 20, which contains a pharmaceutically acceptable oil. 24. The composition of claim 23, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 25. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 19 sufficient to produce a long acting antipsychotic effect. 26. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 20 sufficient to produce a long acting antipsychotic effect. 27. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 24 sufficient to produce a long acting antipsychotic effect.